Pichichero M E, Latiolais T, Bernstein D I, Hosbach P, Christian E, Vidor E, Meschievitz C, Daum R S
University of Rochester, Elmwood Pediatrics, NY, USA.
Pediatr Infect Dis J. 1997 Sep;16(9):863-70. doi: 10.1097/00006454-199709000-00009.
The safety and immunogenicity of a diphtheria-tetanus toxoid-acellular pertussis vaccine (DTaP; Trepedia)/Haemophilus influenzae b polysaccharide (PRP-T; ActHib) combined vaccine (TriHibir; Pasteur Mérieux Connaught) was compared with DTaP and PRP-T given at the same visit but at separate sites in a prospective multicenter, open label trial.
Infants were randomized to four groups (three consistency lots of DTaP/PRP-T vs. one of the consistency lots given as separate vaccines); injections were administered at 2, 4 and 6 months of age. Pre-Dose 1 and post-Dose 3 sera were assayed for antibody titers against all antigens. Reactions to the vaccinations were assessed by parent questionnaire for 30 days after each injection visit.
Four hundred eighty-five infants were enrolled; 296 evaluable infants were included in the DTaP/PRP-T group compared with 70 infants in the DTaP and PRP-T vaccine group. Infants who received the combined vaccine had higher post-Dose 3 geometric mean antibody titers to diphtheria antitoxin (P < 0.01) and pertussis filamentous hemagglutinin (P < 0.05) and lower geometric mean antibody titers to tetanus antitoxin (P < 0.05) and Haemophilus influenzae b (Hib) polysaccharide (PRP) (P < 0.05). The geometric mean anti-PRP antibody titer in the DTaP/PRP-T group was 4.3 micrograms/ml compared with 7.0 micrograms/ml in the separate vaccine group (P < 0.05), and the percentage of infants with antibody titers > or = 0.15 and 1 microgram/ml were, respectively, 95 and 86%, whereas they were 100% for both titers in the separate vaccines group. DTaP/ PRP-T vaccine given concomitantly or 1 month apart from hepatitis B vaccine and oral poliomyelitis vaccine caused no significant differences in immunogenicity or safety. The safety assessments for the DTaP/PRP-T vaccine showed no consistent differences in systemic or local injection site reactions compared with DTaP and PRP-T administered separately.
Although the antibody responses to tetanus and Hib polysaccharide in the evaluated DTaP/PRP-T combined vaccine were significantly lower than those seen after separate DTaP and PRP-T administration, the combined vaccine elicited an immune response against diphtheria, tetanus, pertussis and Haemophilus influenzae b likely to confer protection.
在一项前瞻性多中心开放标签试验中,将白喉-破伤风类毒素-无细胞百日咳疫苗(DTaP;Trepedia)/b型流感嗜血杆菌多糖疫苗(PRP-T;ActHib)联合疫苗(TriHibir;巴斯德梅里埃康诺特公司)的安全性和免疫原性,与在同一就诊时但在不同部位分别接种的DTaP和PRP-T进行比较。
将婴儿随机分为四组(三组DTaP/PRP-T一致性批次与一组作为单独疫苗接种的一致性批次);在2、4和6月龄时进行接种。检测首剂前和第3剂后血清中针对所有抗原的抗体滴度。每次接种后通过家长问卷评估30天内的疫苗接种反应。
共纳入485名婴儿;DTaP/PRP-T组有296名可评估婴儿,而DTaP和PRP-T疫苗组有70名婴儿。接种联合疫苗的婴儿在第3剂后对白喉抗毒素(P<0.01)和百日咳丝状血凝素(P<0.05)的几何平均抗体滴度较高,而对破伤风抗毒素(P<0.05)和b型流感嗜血杆菌(Hib)多糖(PRP)(P<0.05)的几何平均抗体滴度较低。DTaP/PRP-T组的几何平均抗PRP抗体滴度为4.3微克/毫升,而单独疫苗组为7.0微克/毫升(P<0.05),抗体滴度≥0.15微克/毫升和≥1微克/毫升的婴儿百分比分别为95%和86%,而单独疫苗组这两种滴度的婴儿百分比均为100%。与乙肝疫苗和口服脊髓灰质炎疫苗同时接种或间隔1个月接种DTaP/PRP-T疫苗,在免疫原性或安全性方面无显著差异。DTaP/PRP-T疫苗的安全性评估显示,与单独接种DTaP和PRP-T相比,全身或局部注射部位反应无一致差异。
尽管评估的DTaP/PRP-T联合疫苗对破伤风和Hib多糖的抗体反应明显低于单独接种DTaP和PRP-T后的反应,但联合疫苗引发了针对白喉、破伤风、百日咳和b型流感嗜血杆菌的免疫反应,可能提供保护。